Business News • PR NewsWire • Data Demonstrating That SEPREHVIR® (VIRTTU Biologics) Combines Synergistically With Anti-PD-1 Immune Checkpoint Inhibitor To Be Presented At AACR's Advances In Pediatric Cancer Research.

Data Demonstrating That SEPREHVIR® (VIRTTU Biologics) Combines Synergistically With Anti-PD-1 Immune Checkpoint Inhibitor To Be Presented At AACR's Advances In Pediatric Cancer Research.

Data Demonstrating That SEPREHVIR® (VIRTTU Biologics) Combines Synergistically With Anti-PD-1 Immune Checkpoint Inhibitor To Be Presented At AACR's Advances In Pediatric Cancer Research.

GLASGOW, Scotland, Nov. 9, 2015 /PRNewswire/ -- VIRTTU Biologics, a clinical stage oncolytic immunotherapeutic company developing SEPREHVIR, a tumor-targeted herpes simplex vector, is pleased to announce the presentation of a poster by a key collaborator, Dr. Tim Cripe (Nationwide...

View More : http://www.prnewswire.com/news-releases/data-demonstrating-that-seprehvir-virttu-biologics-combines-synergistically-with...

Releted News by prnewswire

World Food Championships Names 2015 Category Winners

UMC Reports Sales for October 2015

SnugZ Delivers High Quality Prints For Creation Of Promotional Products With Epson SurePress Digital Label Printers

Data Demonstrating That SEPREHVIR® (VIRTTU Biologics) Combines Synergistically With Anti-PD-1 Immune Checkpoint Inhibitor To Be Presented At AACR's Advances In Pediatric Cancer Research.

Nova Southeastern University Ranks Among Top 25 Percent in Undergraduate Student Earnings

Artificial Intelligence and Deep Learning Technology Race to Determine Winners and Losers in Quest for Driverless Cars

Birch Named to Atlanta Business Chronicle's 2015 List of 50 Top Private Companies